Table 1.
Characteristics of Included Participants. Baseline characteristics of study participants reported as numbers or median values (25th to 75th percentiles) allocated to azathioprine and allopurinol (L-AZA/ALLO) versus azathioprine (AZA) alone in intention to treat study population.
| L-AZA/ALLO (N = 47) | AZA (N = 42) | |
|---|---|---|
| Sex (male/female) | 23/24 | 16/26 |
| Ethnicity (Caucasians) | 47 | 42 |
| Age (years) | 30 (25‒48) | 37 (29‒42) |
| Smoking status | ||
| Never smoked | 24 | 21 |
| Previous | 7 | 2 |
| Smoker (ongoing) | 17 | 18 |
| Body Mass Index (kg/m2) | 24 (22‒26) | 25 (22‒27) |
| Ulcerative Colitis Phenotype | ||
| E1 - proctitis | 1 | 3 |
| E2 - left-sided | 24 | 18 |
| E3 - extensive | 23 | 20 |
| Disease duration (years) | 1 (1‒8) | 2 (1‒6.5) |
| Partial Mayo Score (inclusion visit) | 5 (1‒6) | 5 (1‒7) |
| Previous systemic prednisolone (total number) | 2 (1‒3) | 2 (1‒3) |
| Concomitant oral 5-ASA | 40 | 32 |
| AZA dose | 50 (50‒50) | 200 (175‒200) |
| Infliximab treatment | 15 | 16 |